Antiviral Drug Allergy: Acyclovir Cross-Reactivity & Paxlovid DDIs

Yes — for allergy purposes, acyclovir and valacyclovir are the same drug. Valacyclovir is a prodrug that undergoes complete first-pass hepatic hydrolysis to acyclovir, so both drugs present identical active molecules to the immune system. If you have documented allergy to acyclovir, valacyclovir will cause the same reaction, and vice versa. Both drugs are commonly prescribed for herpes simplex virus and varicella-zoster suppression. The clinical switch option is famciclovir, which metabolizes to penciclovir — a structurally distinct guanosine analog that approximately 50% of acyclovir-allergic patients can tolerate based on published experience.

No. Paxlovid rebound refers to the recurrence of COVID-19 symptoms after completing the standard 5-day course of nirmatrelvir/ritonavir. It occurs in up to approximately 10% of patients and represents a viral rebound phenomenon — SARS-CoV-2 transiently increases in the respiratory tract after drug levels decline. This is not an allergic reaction, not reinfection, and does not indicate drug allergy or treatment failure. The CDC has noted that Paxlovid rebound typically resolves on its own without additional treatment, and mild recurrence does not require a second course.

The neuropsychiatric events associated with oseltamivir (Tamiflu) — agitation, delirium, hallucinations, and abnormal behavior primarily in pediatric patients — are not allergic reactions. They represent an idiosyncratic CNS phenomenon triggered by oseltamivir, with unclear mechanism possibly involving CNS oseltamivir penetration. Whether to rechallenge depends on the severity of the previous episode and clinical necessity. Zanamivir (Relenza, inhaled) and baloxavir marboxil (Xofluza, oral) are structurally distinct influenza alternatives that do not share this CNS effect profile. Discuss the risk-benefit assessment with your physician or pediatrician.

Remdesivir infusion reactions — which include hypotension, nausea, sweating, chills, and occasionally dyspnea occurring during or shortly after IV administration — are largely driven by cytokine release and possibly direct mast cell activation rather than IgE-mediated anaphylaxis. This mechanism is similar to amphotericin B infusion reactions. Serum tryptase measured during a remdesivir reaction is typically normal, a key feature distinguishing cytokine-release from true anaphylaxis. The FDA EUA guidance recommends slowing the infusion rate and observing patients for at least one hour post-infusion in a clinical setting.

The vast majority of Paxlovid adverse effects reported in practice are drug-drug interactions, not allergic reactions. Paxlovid contains ritonavir, a potent CYP3A4 inhibitor that dramatically increases blood levels of many common medications including statins, anticoagulants, calcineurin inhibitors, and some antidepressants. Elevated levels of these interacting drugs cause symptoms that may superficially resemble drug allergy but are pharmacologically driven. The solution is medication reconciliation — temporarily adjusting or holding interacting drugs during the 5-day Paxlovid course — not labeling the patient as allergic to nirmatrelvir or ritonavir.

Yes — antiviral subclasses are mechanistically and structurally distinct, so allergy to acyclovir does not prevent use of influenza antivirals (oseltamivir, zanamivir, baloxavir marboxil), COVID-19 antivirals (nirmatrelvir/ritonavir Paxlovid, molnupiravir), hepatitis antivirals (sofosbuvir-based DAA regimens, entecavir, tenofovir), or CMV agents (ganciclovir, valganciclovir, letermovir). Even within the herpesvirus agent subclass itself, famciclovir is metabolized to penciclovir — a structurally distinct guanosine analog that approximately half of acyclovir-allergic patients can tolerate based on published clinical experience. A board-certified allergist can perform drug provocation testing to map your specific cross-reactivity profile and confirm which agents you can use safely.

Antiviral allergy diagnosis depends on the specific drug and reaction type. For acyclovir and valacyclovir, drug provocation testing (an observed graded oral challenge) is the gold standard, as skin testing protocols are not standardized for most antivirals. Serum tryptase measured during an acute reaction helps classify whether it is IgE-mediated anaphylaxis or cytokine release. For mild reactions, clinical history and rechallenge with a potentially safer alternative (like famciclovir for acyclovir-reacting patients) may be sufficient. Formal allergist evaluation is recommended for all patients who experienced systemic symptoms or anaphylaxis from any antiviral medication.

Direct-acting antiviral (DAA) regimens for hepatitis C — including sofosbuvir-based combinations like Epclusa, Harvoni, and Mavyret — have a very low hypersensitivity signal. Most adverse effects with these agents are pharmacologic: ribavirin (used in some older regimens) causes hemolytic anemia through oxidative erythrocyte damage and is teratogenic, but these are not allergic phenomena. Skin rashes in early DAA trials were sometimes attributable to interferon co-administration rather than the DAAs themselves. True IgE-mediated allergy to modern interferon-free DAA regimens is extraordinarily rare and should be formally evaluated by an allergist.